Can I Take Creatine with Alprostadil (Caverject/MUSE)?

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic prostaglandin E1 (PGE1) approved by the FDA for men with erectile dysfunction (ED) that does not respond adequately to oral phosphodiesterase-5 inhibitors like sildenafil or tadalafil. It is available as an intracavernosal injection (Caverject, Caverject Impulse, Edex) dosed at 2.5 to 40 mcg per injection, and as an intraurethral suppository (MUSE) dosed at 125 to 1,000 mcg [1].

Mechanism of Action

Alprostadil binds prostaglandin EP2 and EP3 receptors on smooth muscle cells in penile arterioles and the corpus cavernosum. This activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and triggers smooth muscle relaxation and arterial dilation. The result is increased blood flow into the corpus cavernosum, producing erection within 5 to 20 minutes of administration [2].

Because alprostadil acts locally inside penile tissue rather than systemically through the hepatic first-pass pathway, its systemic bioavailability is low. Intracavernosal alprostadil reaches peripheral venous plasma in concentrations roughly equal to endogenous circulating PGE1, and it is metabolized rapidly (plasma half-life of approximately 30 to 60 seconds for unbound drug) primarily by oxidation in the lung and liver [1].

Why Renal and Cardiovascular Status Matters

The FDA prescribing information for Caverject notes that alprostadil should be used cautiously in patients with conditions predisposing to priapism, including those with anatomical deformation of the penis, and in patients with underlying cardiovascular or renal disease. Renal impairment does not directly alter alprostadil's local pharmacokinetics in a clinically meaningful way for most patients, but it is a marker of systemic vascular health relevant to the condition being treated [1].

What Is Creatine and What Does It Do to Kidney Markers?

Creatine monohydrate is one of the most widely studied sports supplements on the market. At a maintenance dose of 3 to 5 g per day, it replenishes phosphocreatine stores in skeletal muscle, allowing faster ATP resynthesis during high-intensity exercise [3].

The Creatinine Artifact Problem

Creatinine, the waste byproduct used to estimate glomerular filtration rate (GFR), is produced both from muscle creatine turnover and from dietary creatine catabolism. When exogenous creatine intake increases, creatinine production rises even if actual kidney filtration function is unchanged.

A crossover study by Poortmans and Francaux (N=18 male athletes) found that 5 g/day of creatine for 5 weeks raised 24-hour urinary creatinine excretion significantly without changing creatinine clearance or urinary albumin, suggesting the rise reflects increased creatine catabolism rather than nephrotoxicity [4]. A systematic review by Rawson et al. Covering 12 controlled trials found no evidence that creatine supplementation at recommended doses harms kidney function in healthy individuals [5].

The practical implication: serum creatinine on a standard metabolic panel may appear elevated by 10 to 20% in a man taking creatine, which could falsely lower his calculated eGFR by a similar margin. A man with a baseline eGFR of 65 mL/min/1.73 m² might show a lab value of 52 to 58 mL/min/1.73 m² on creatine, a shift from CKD stage 2 to stage 3a on paper alone.

Cystatin C as the Preferred Monitoring Marker

Cystatin C is a small protein filtered freely by the glomerulus and not influenced by muscle mass or creatine intake. The American Diabetes Association and the National Kidney Foundation both recommend cystatin C-based eGFR equations when creatinine-based estimates may be unreliable [6]. For any man using alprostadil who chooses to take creatine, cystatin C provides a cleaner window into actual kidney function.

Is There a Direct Pharmacokinetic or Pharmacodynamic Interaction?

No direct pharmacokinetic interaction between creatine and alprostadil has been identified in published literature or major interaction databases.

Pharmacokinetic Assessment

Alprostadil is not metabolized by cytochrome P450 enzymes. Its primary metabolic pathway involves 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) and beta-oxidation in the lung and liver [2]. Creatine has no known inhibitory or inductive effect on these enzymes or transporters. There is no shared plasma-protein binding, no overlapping metabolic pathway, and no published case report of altered alprostadil exposure in a creatine user.

The FDA's drug interaction database and the Natural Medicines Comprehensive Database list no interaction between creatine and alprostadil [7].

Pharmacodynamic Assessment

Alprostadil acts on adenylyl cyclase pathways in smooth muscle. Creatine's mechanism of action is entirely intramuscular, centered on the creatine kinase reaction: creatine + ATP → phosphocreatine + ADP. These pathways do not converge in any tissue where alprostadil exerts its primary effect.

There is no evidence that creatine alters blood pressure, vascular tone, platelet function, or coagulation in ways that would potentiate or reduce alprostadil's hemodynamic activity. A 2003 Cochrane-registered review of creatine and cardiovascular parameters found no significant effects on resting blood pressure in healthy adults [3].

Indirect Risks Worth Knowing

Even without a direct interaction, two indirect risks deserve a focused discussion.

Risk 1: Masking Worsening Renal Function

Men prescribed alprostadil for ED often have underlying conditions, including type 2 diabetes, hypertension, or cardiovascular disease, that themselves cause progressive chronic kidney disease. If creatine is elevating serum creatinine by 10 to 20%, a genuine decline in renal function could be partially masked during routine lab monitoring.

The American College of Cardiology/American Heart Association 2023 hypertension guidelines recommend annual eGFR monitoring for patients with cardiometabolic risk factors [8]. A man with diabetes on alprostadil who also takes creatine should have both creatinine-based and cystatin C-based eGFR checked at least once per year, so clinicians can separate the creatine artifact from real function change.

Risk 2: Dehydration and Osmotic Load

Creatine draws water into muscle cells. During the loading phase (20 g/day for 5 to 7 days), some users experience a 0.5 to 1.5 kg increase in total body water [3]. For most men this is benign, but for a man with borderline renal function, transient shifts in serum osmolality could theoretically stress already compromised kidneys. Staying well-hydrated (2 to 3 liters of water daily during loading) is standard guidance from the International Society of Sports Nutrition [9].

The table below provides the HealthRX clinical decision framework for men combining creatine with alprostadil, stratified by baseline renal function.

| Baseline eGFR (creatinine-based) | Recommendation | |---|---| | >90 mL/min/1.73 m² (normal) | Creatine at 3 to 5 g/day is acceptable. Recheck BMP at 8 weeks to document creatinine change. | | 60 to 89 mL/min/1.73 m² (mildly reduced) | Obtain baseline cystatin C before starting creatine. Recheck cystatin C at 4 weeks. Skip 20 g/day loading. | | 30 to 59 mL/min/1.73 m² (CKD stage 3) | Discuss with prescribing physician before starting creatine. Use cystatin C-based eGFR exclusively for monitoring. | | <30 mL/min/1.73 m² (CKD stage 4 to 5) | Creatine is generally not recommended without nephrology input. |

Who Uses Alprostadil, and Why This Population Needs Careful Monitoring

ED affects approximately 30 million men in the United States, according to data from the National Institute of Diabetes and Digestive and Kidney Diseases [10]. A significant portion of men who progress to alprostadil-based therapy have already failed oral PDE5 inhibitors, which means they typically carry a higher burden of vascular disease.

The Cardiometabolic Overlap

A 2018 analysis published in the Journal of Sexual Medicine found that men requiring intracavernosal therapy were more likely to have type 2 diabetes, hypertension, and dyslipidemia compared with men who responded to oral agents. Type 2 diabetes alone is present in approximately 35 to 45% of men with refractory ED [11].

This matters because diabetic nephropathy affects roughly 40% of people with type 2 diabetes over time, per the American Diabetes Association Standards of Care [6]. A man with both diabetes and refractory ED who is using creatine has three independent reasons why his creatinine level may not tell the full story of his kidney health.

Creatine Supplementation in Older Men

Creatine is increasingly used by men over 50 for its potential benefits in preserving muscle mass and strength. A 12-week randomized controlled trial (N=30, mean age 70 years) found that creatine combined with resistance training significantly improved lean body mass compared to placebo, P<0.05 [12]. Men in this age group are also the primary demographic prescribed alprostadil, so the overlap is real and growing.

Practical Guidance: Taking Both Safely

If you currently use alprostadil and want to add creatine, or you use creatine and your physician has just prescribed alprostadil, follow these steps.

Step 1: Get a Baseline Renal Panel First

Before starting creatine (or before starting alprostadil if creatine is already in use), obtain a complete metabolic panel including serum creatinine, BUN, and eGFR. Ask your provider to add a serum cystatin C. This gives you a documented pre-creatine baseline.

Step 2: Skip the Loading Phase if Your eGFR Is Below 75

The 20 g/day loading protocol produces faster creatinine elevation. Skipping directly to the 3 to 5 g/day maintenance dose produces the same long-term phosphocreatine saturation at 4 weeks compared with 1 week for the loading protocol, as confirmed in a head-to-head comparison by Hultman et al. (N=31) [13]. For men with any kidney concern, slower is safer.

Step 3: Recheck Labs at 4 to 8 Weeks

A repeat basic metabolic panel at 4 to 8 weeks documents how much your creatinine has risen on creatine. Most of that rise is the artifact described above. If cystatin C-based eGFR is stable, actual kidney function is almost certainly unchanged.

Step 4: Tell Your Prescribing Physician

This seems obvious but is often skipped. Alprostadil is a prescription medication administered by injection or intraurethral insertion. Your urologist or primary care physician needs to know about all supplements, including creatine, when reviewing your labs. A 10 to 20% creatinine artifact that goes unexplained may trigger unnecessary imaging, nephrology referral, or medication dose adjustments.

Step 5: Watch for Alprostadil-Specific Side Effects Separately

Creatine will not change the risk profile of alprostadil itself. The most common adverse effects of intracavernosal alprostadil are penile pain (reported in up to 37% of users in clinical trials), prolonged erection, and, rarely, priapism (erection lasting longer than 4 hours) [1]. If an erection persists beyond 4 hours, this is a medical emergency requiring immediate treatment regardless of creatine use.

What the Guidelines Say

No published guideline from the American Urological Association (AUA), the Endocrine Society, or the European Association of Urology specifically addresses the creatine-alprostadil combination, because no direct pharmacological interaction exists. The absence of a guideline statement reflects the absence of a pharmacological signal, not a gap in the evidence.

The 2018 AUA Guideline on Erectile Dysfunction recommends that clinicians assess overall cardiometabolic health before initiating any ED therapy and that laboratory monitoring should be individualized based on the patient's comorbid conditions [14]. Under that framework, adding creatine to the mix simply means adjusting the interpretation of standard renal labs, not avoiding the supplement altogether.

The International Society of Sports Nutrition Position Stand on creatine (updated 2017) states: "Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass during training." It also explicitly notes that short- and long-term supplementation is safe in healthy individuals and that it does not harm kidney function at recommended doses [9].

Special Populations and Edge Cases

Men with One Kidney

A single functioning kidney reduces total filtration capacity by roughly 50% at baseline. While creatine has not been shown to harm the remaining kidney in published cohort data, the creatinine artifact becomes proportionally larger and more misleading. Cystatin C monitoring is mandatory in this group. Creatine use should be discussed with a nephrologist before starting.

Men Using Alprostadil After Prostatectomy

Radical prostatectomy is one of the most common reasons men progress to alprostadil therapy, as nerve-sparing procedures are not always fully successful. These men tend to be otherwise healthy and may be actively pursuing post-surgical rehabilitation that includes resistance training and creatine use. For this subgroup, the risk of creatine-related renal harm is low, but the standard baseline-and-recheck monitoring protocol still applies.

Men on ACE Inhibitors or ARBs

ACE inhibitors (e.g., lisinopril) and angiotensin receptor blockers (e.g., losartan) are frequently co-prescribed in men with hypertension or diabetes, the same comorbidities that drive refractory ED. These medications independently raise serum creatinine by 10 to 30% through their hemodynamic effects on glomerular filtration. A man on an ACE inhibitor who adds creatine could see a combined creatinine elevation of 20 to 40% above his true functional baseline. Cystatin C-based eGFR becomes the only reliable renal monitoring tool in this scenario [6].

Clinician Perspective

Dr. Richard Casey, a urologist cited in a 2022 clinical review on penile rehabilitation, noted that "the intersection of fitness supplementation and prescription ED therapy is increasingly common in my practice, and most patients simply do not mention the supplements they take unless directly asked."

This reflects a real clinical gap. Structured supplement review at every alprostadil follow-up visit, with explicit documentation of creatine use, lets clinicians correctly interpret labs rather than chase creatinine elevations that are artifactual.